Trial Profile
Phase I trial of AE-37 in patients with ovarian cancer.
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 25 Apr 2019
Price :
$35
*
At a glance
- Drugs AE 37 (Primary)
- Indications Ovarian cancer
- Focus Pharmacodynamics
- 25 Jan 2011 Generex media release reference added
- 03 Mar 2009 First patient dosed as reported by Generex Biotechnology media release.
- 07 Aug 2008 Status changed from planning to recruiting as enrolment has now begun, according to Generex media release.